Antidiabetika bei Patienten mit Niereninsuffizienz
详细信息 查看全文
- 作者：PD Dr. D. Czock (1)
- 关键词：Diabetes mellitus ; Antidiabetika ; Niereninsuffizienz ; Dosisanpassung ; Kontraindikationen ; Diabetes mellitus ; Hypoglycemic agents ; Renal insufficiency ; Dose adjustment ; Contraindications
- 刊名：Der Nephrologe
- 出版年：2014
- 出版时间：November 2014
- 年：2014
- 卷：9
- 期：6
- 页码：433-441
- 全文大小：497 KB
- 参考文献：1. Fachinformation zu Glucophage庐, Stand Oktober 2010
2. Aronoff GR, Bennett WM, Berns JS et al (2007) Drug prescribing in renal failure, 5th edn. American College of Physicians, Philadelphia.
3. Hartmann B, Czock D, Keller F (2010) Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int 107:647鈥?55
4. Schwartz SL, Gordi T, Hou E et al (2008) Clinical development of metformin extended-release tablets for type 2 diabetes: an overview. Expert Opin Drug Metab Toxicol 4:1235鈥?243 CrossRef
5. Harrower AD (1996) Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 31:111鈥?19 CrossRef
6. Fachinformation zu Actos庐, Stand November 2013
7. Fritsche L, Budde K, Glander P et al (2003) Treating type 2 diabetes in renal insufficiency: the role of pioglitazone. Int J Clin Pharmacol Ther 41:488鈥?91 CrossRef
8. Budde K, Neumayer HH, Fritsche L et al (2003) The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55:368鈥?74 CrossRef
9. Abe M, Kikuchi F, Okada K et al (2008) Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis. Diabetes Res Clin Pract 80:432鈥?38 CrossRef
10. Abe M, Kikuchi F, Okada K, Matsumoto K (2009) Plasma concentration of pioglitazone in patients with type 2 diabetes on hemodialysis. Ther Apher Dial 13:238鈥?39 CrossRef
11. Fachinformation zu Euglucon庐, Stand November 2013
12. Holstein A, Plaschke A, Hammer C, Egberts EH (2003) Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 59:91鈥?7 CrossRef
13. Fachinformation zu Amaryl庐, Stand Oktober 2013
14. Rosenkranz B, Profozic V, Metelko Z et al (1996) Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 39:1617鈥?624 CrossRef
15. Fachinformation zu Glurenorm庐, Stand Mai 2008
16. Malaisse WJ (2006) Gliquidone庐 contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data. Drugs R D 7:331鈥?37 CrossRef
17. Kopitar Z, Koss FW (1975) Pharmacokinetic behaviour of gliquidone (AR-DF 26), a new sulfonyl urea. Summary of the studies so far (author鈥檚 transl). Arzneimittelforschung 25:1933鈥?938
18. Fachinformation zu NovoNorm庐, Stand April 2012
19. Schumacher S, Abbasi I, Weise D et al (2001) Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 57:147鈥?52 CrossRef
20. Marbury TC, Ruckle JL, Hatorp V et al (2000) Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 67:7鈥?5 CrossRef
21. Hatorp V (2002) Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 41:471鈥?83 CrossRef
22. Culy CR, Jarvis B (2001) Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 61:1625鈥?660 CrossRef
23. Hasslacher C; Multinational Repaglinide Renal Study Group (2003) Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 26:886鈥?91 CrossRef
24. Fachinformation zu Starlix庐, Stand Oktober 2011
25. McLeod JF (2004) Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin Pharmacokinet 43:97鈥?20 CrossRef
26. Inoue T, Shibahara N, Miyagawa K (2003) Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 60:90鈥?5 CrossRef
27. Fachinformation zu Byetta庐, Stand Dezember 2013
28. Fachinformation zu Bydureon庐, Stand Januar 2014
29. Linnebjerg H, Kothare PA, Park S et al (2007) Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 64:317鈥?27 CrossRef
30. Fachinformation zu Victoza庐, Stand M盲rz 2013
31. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M (2009) Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 68:898鈥?05 CrossRef
32. Terawaki Y, Nomiyama T, Akehi Y et al (2013) The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr 5:10 CrossRef
33. Fachinformation zu Lyxumia庐, Stand September 2013
34. Fachinformation zu Januvia庐 100聽mg, Stand Juli 2013
35. Bergman AJ, Cote J, Yi B et al (2007) Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30:1862鈥?864 CrossRef
36. Chan JC, Scott R, Arjona Ferreira JC et al (2008) Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 10:545鈥?55 CrossRef
37. Scheen AJ (2010) Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12:648鈥?58 CrossRef
38. Arjona Ferreira JC, Marre M, Barzilai N et al (2013) Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diab Care 36:1067鈥?073 CrossRef
39. Arjona Ferreira JC, Corry D, Mogensen CE et al (2013) Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 61:579鈥?87 CrossRef
40. Fachinformation zu Onglyza庐, Stand Juli 2013
41. Neumiller JJ, Campbell RK (2010) Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Am J Health Syst Pharm 67:1515鈥?525 CrossRef
42. Boulton DW, Li L, Frevert EU et al (2011) Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 50:253鈥?65 CrossRef
43. Nowicki M, Rychlik I, Haller H et al (2011) Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 65:1230鈥?239 CrossRef
44. Fachinformation zu Glucobay庐, Stand Juli 2013
45. Charpentier G, Riveline JP, Varroud-Vial M (2000) Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 26(Suppl 4):73鈥?5
46. Fachinformation zu Diastabol庐, Stand Oktober 2010
47. Fachinformation zu Forxiga庐, Stand Dezember 2013
48. Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:962鈥?71 CrossRef
49. Fachinformation zu Invokana庐, Stand November 2013
50. Hiatt WR, Kaul S, Smith RJ (2013) The cardiovascular safety of diabetes drugs 鈥?insights from the rosiglitazone experience. N Engl J Med 369:1285鈥?287 CrossRef
51. Dowling TC, Wang ES, Ferrucci L, Sorkin JD (2013) Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore Longitudinal Study on Aging: impact on renal drug dosing. Pharmacotherapy 33:912鈥?21 CrossRef
52. Park EJ, Wu K, Mi Z et al (2012) A systematic comparison of cockcroft-gault and modification of diet in renal disease equations for classification of kidney dysfunction and dosage adjustment. Ann Pharmacother 46:1174鈥?187 CrossRef - 作者单位：PD Dr. D. Czock (1)
1. Medizinische Klinik, Abt. Klinische Pharmakologie und Pharmakoepidemiologie, Universit盲tsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland - ISSN：1862-0418
文摘
Background Many antidiabetic drugs have to be adjusted for administration to patients with renal impairment. Objectives Drug dose adjustment of antidiabetic drugs to renal function, specific risks and contraindications. Material and methods Review of current recommendations based on the German summary of product characteristics and published articles from the scientific literature. Results The selection of an antidiabetic drug should be made after individual consideration of expected benefits and potential risks. Metformin is contraindicated in patients with renal impairment. Pioglitazone may be used but a number of potential risks have to be considered. Gliquidone and repaglinide are considered as being kidney-independent. Glucagon-like peptide 1 (GLP-1) analogues should be avoided in patients with severe renal impairment but dipeptidyl peptidase 4 (DPP-4) inhibitors may be used (with dose adjustment). Sodium-glucose linked transporter 2 (SGLT2) inhibitors are inefficient in patients with renal impairment and alpha glucosidase inhibitors are contraindicated in cases of severe renal impairment. Conclusion Oral antidiabetic drugs can also be prescribed for patients with renal impairment but recommended drug dose adjustments and contraindications must be considered.